Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγproduction  

作　　者：Yelei Guo Chuan Tong Zhiqiang Wu Yuting Lu Yao Wang Weidong Han 

机构地区：[1]Department of Bio-therapeutic,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China

出　　处：《Cancer Biology & Medicine》2023年第11期779-782,共4页癌症生物学与医学（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Grant Nos.82150108,31991171,and 81830002 to W.H.,and Grant No.82102892 to C.T.)。

摘　　要：Adoptive cell transfer(ACT)using chimeric antigen receptor(CAR)modified T cells and T cell receptor(TCR)engineered T cells has shown therapeutic efficacy in cancer treatment1,2.CAR T cells are widely applicable to tumor patients because of their ability to directly identify tumor cells in an MHCindependent manner.

关 键 词：SUSTAINED ENDOGENOUS CAR 

分 类 号：R730.51[医药卫生—肿瘤]